NG25

NG25 is a small molecule drug that functions as a **potent inhibitor of TAK1 (MAP3K7) and MAP4K2**, with IC50 values of 149 nM (TAK1) and 21.7 nM (MAP4K2)[8][9]. It was initially developed by MD Anderson Cancer Center Orlando[1]. Mechanistically, NG25 directly inhibits **TAK1 kinase activity**, thereby blocking downstream MAPK signaling cascades. Preclinical data indicate its ability to suppress growth of KRAS-mutant colorectal cancer in vitro and in vivo, as well as its potential utility in neoplastic and inflammatory conditions[2]. The agent is being explored mainly for its **antineoplastic/anticancer effects**, with a specific focus on cancer types such as **breast cancer**[1][2].